Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma
Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the publication of a scientific article titled “Patient-specific autologous thymic organoids support functional T-cell education leading to antitumor activity in humanized mice with melanoma xenografts” in Cancer Research Communications, a journal of the American Association for Cancer Research. The research was led by Antonio Jimeno, M.D., Ph.D., from the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz School of Medicine, and Holger A. Russ, Ph.D., from the Diabetes Institute and the Department of Pharmacology and Therapeutics, College of Medicine at the University of Florida, Gainesville, and scientific co-founder of Tolerance Bio.
Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics
Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, and ZipCode Bio, a biotechnology company developing next-generation RNA medicines, today announced a strategic research and development collaboration aimed at pioneering novel delivery methods for targeted thymus therapeutics.
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases
Tolerance Bio, Inc., a biopharmaceutical company pioneering innovative approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the formation of its Scientific Advisory Board (SAB) and the completion of its oversubscribed $20.2 million seed financing round.
Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases
Tolerance Bio, Inc., a biopharmaceutical company pioneering a novel approach to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the closing of its oversubscribed $17.2 million seed financing round, led by Columbus Venture Partners, with participation from Criteria Bio Ventures, Sessa Capital, BioAdvance, Ben Franklin Technology Partners and individual biotechnology investors.
